Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ABP) is a clinical-stage biopharmaceutical company that entered the public markets through a de-SPAC business combination, with its shares listing in 2025 following the closing of its merger transaction. Operating in the life sciences and biotechnology sector, the company focuses on the development of differentiated antibody therapeutics using its proprietary antibody engineering platform. Abpro filed an 8-K current report with the Securities and Exchange Commission on October 14, 2025, fulfilling its ongoing disclosure obligations as a public reporting issuer. For full deal metrics, sponsor history, and filing data on ABP and every other SPAC-linked name, create a free account at SpacDesk.